PPARα signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells

Biochemical Pharmacology

Volumn 77, Issue 9, 2009, Pages 1480-1486

  Tuller, Erin R ^a   Brock, Andrea L ^a   Yu, Haijun ^a   Lou, Jessica R ^a   Benbrook, Doris M ^a   Ding, Wei Qun ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Clioquinol; DHA; PPAR ; Synergy

Indexed keywords

CLIOQUINOL; CLOFIBRATE; DOCOSAHEXAENOIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TROGLITAZONE; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; DRUG CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; WESTERN BLOTTING; APOPTOSIS; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CLIOQUINOL; DOCOSAHEXAENOIC ACIDS; DRUG SYNERGISM; HUMANS; PPAR ALPHA; SIGNAL TRANSDUCTION;

EID: 63149185866     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.02.002     Document Type: Article

References (51)

1. Blagosklonny M.V. Overcoming limitations of natural anticancer drugs by combining with artificial agents. Trends Pharmacol Sci 26 (2005) 77-81
2. Leu K.M., Ostruszka L.J., Shewach D., Zalupski M., Sondak V., Biermann J.S., et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 22 (2004) 1706-1712
3. Bradley M.O., Webb N.L., Anthony F.H., Devanesan P., Witman P.A., Hemamalini S., et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 7 (2001) 3229-3238
4. Wolff A.C., Donehower R.C., Carducci M.K., Carducci M.A., Brahmer J.R., Zabelina Y., et al. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 9 (2003) 3589-3597
5. Banerjee S., Zhang Y., Ali S., Bhuiyan M., Wang Z., Chiao P.J., et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65 (2005) 9064-9072
6. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., and Sarkar F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65 (2005) 6934-6942
7. Hwang J.T., Ha J., and Park O.J. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res Commun 332 (2005) 433-440
8. Azrak R.G., Cao S., Slocum H.K., Toth K., Durrani F.A., Yin M.B., et al. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res 10 (2004) 1121-1129
9. Sarkar F.H., and Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 66 (2006) 3347-3350
10. Reddy B.S., Burill C., and Rigotty J. Effect of diets high in omega-3 and omega-6 fatty acids on initiation and postinitiation stages of colon carcinogenesis. Cancer Res 51 (1991) 487-491
11. Hirose M., Masuda A., Ito N., Kamano K., and Okuyama H. Effects of dietary perilla oil, soybean oil and safflower oil on 7,12-dimethylbenz[a]anthracene (DMBA) and 1,2-dimethyl-hydrazine (DMH)-induced mammary gland and colon carcinogenesis in female SD rats. Carcinogenesis 11 (1990) 731-735
12. Karmali R.A., Marsh J., and Fuchs C. Effect of omega-3 fatty acids on growth of a rat mammary tumor. J Natl Cancer Inst 73 (1984) 457-461
13. Hudson E.A., and Tisdale M.J. Comparison of the effectiveness of eicosapentaenoic acid administered as either the free acid or ethyl ester as an anticachectic and antitumour agent. Prostaglandins Leukot Essent Fatty Acids 51 (1994) 141-145
14. Gonzalez M.J., Schemmel R.A., Dugan Jr. L., Gray J.I., and Welsch C.W. Dietary fish oil inhibits human breast carcinoma growth: a function of increased lipid peroxidation. Lipids 28 (1993) 827-832
15. Rose D.P., and Connolly J.M. Effects of dietary omega-3 fatty acids on human breast cancer growth and metastases in nude mice. J Natl Cancer Inst 85 (1993) 1743-1747
16. Baumgartner M., Sturlan S., Roth E., Wessner B., and Bachleitner-Hofmann T. Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. Int J Cancer 112 (2004) 707-712
17. Sturlan S., Baumgartner M., Roth E., and Bachleitner-Hofmann T. Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. Blood 101 (2003) 4990-4997
18. Germain E., Chajes V., Cognault S., Lhuillery C., and Bougnoux P. Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation. Int J Cancer 75 (1998) 578-583
19. Maheo K., Vibet S., Steghens J.P., Dartigeas C., Lehman M., Bougnoux P., et al. Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation. Free Radic Biol Med 39 (2005) 742-751
20. Florent S., Malaplate-Armand C., Youssef I., Kriem B., Koziel V., Escanye M.C., et al. Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-beta oligomers. J Neurochem 96 (2006) 385-395
21. Akbar M., Calderon F., Wen Z., and Kim H.Y. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci U S A 102 (2005) 10858-10863
22. Ding W.Q., Liu B., Vaught J.L., Palmiter R.D., and Lind S.E. Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. Mol Cancer Ther 5 (2006) 1864-1872
23. Regland B., Lehmann W., Abedini I., Blennow K., Jonsson M., Karlsson I., et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord 12 (2001) 408-414
24. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60 (2003) 1685-1691
25. Chen D., Cui Q.C., Yang H., Barrea R.A., Sarkar F.H., Sheng S., et al. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res 67 (2007) 1636-1644
26. Ding W.Q., Liu B., Vaught J.L., Yamauchi H., and Lind S.E. Anticancer activity of the antibiotic clioquinol. Cancer Res 65 (2005) 3389-3395
27. Du T., Filiz G., Caragounis A., Crouch P.J., and White A.R. Clioquinol promotes cancer cell toxicity through tumor necrosis factor alpha release from macrophages. J Pharmacol Exp Ther 324 (2008) 360-367
28. Mao X., Li X., Sprangers R., Wang X., Venugopal A., Wood T., et al. Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma. Leukemia (2008) 1
29. Diep Q.N., Touyz R.M., and Schiffrin E.L. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension 36 (2000) 851-855
30. Kim J.B., Wright H.M., Wright M., and Spiegelman B.M. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci U S A 95 (1998) 4333-4337
31. Yoshioka T., Wada T., Uchida N., Maki H., Yoshida H., Ide N., et al. Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Cancer Res 58 (1998) 2583-2587
32. Padmanabhan G., Becue L., and Smith J.B. Clioquinol. Analytical Profiles of Drug Substances vol. 18 (1989) pp. 57-90
33. Brewer G.J., Dick R.D., Grover D.K., LeClaire V., Tseng M., Wicha M., et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 6 (2000) 1-10
34. Chen D., and Dou Q.P. New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer. Expert Opin Ther Targets 12 (2008) 739-748
35. Ding W.Q., Yu H.J., and Lind S.E. Zinc-binding compounds induce cancer cell death via distinct modes of action. Cancer Lett 271 (2008) 251-259
36. Gani O.A., and Sylte I. Molecular recognition of Docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha. J Mol Graph Model (2008)
37. Gani O.A., and Sylte I. Ligand-induced stabilization and activation of peroxisome proliferator-activated receptor gamma. Chem Biol Drug Des 72 (2008) 50-57
38. Sertznig P., Seifert M., Tilgen W., and Reichrath J. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol 212 (2007) 1-12
39. Gottlicher M., Widmark E., Li Q., and Gustafsson J.A. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci U S A 89 (1992) 4653-4657
40. Adams M., Montague C.T., Prins J.B., Holder J.C., Smith S.A., Sanders L., et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100 (1997) 3149-3153
41. Canuto R.A., Muzio G., Maggiora M., Trombetta A., Martinasso G., Autelli R., et al. Apoptosis induced by clofibrate in Yoshida AH-130 hepatoma cells: role of HMG-CoA reductase. J Lipid Res 44 (2003) 56-64
42. Muzio G., Maggiora M., Trombetta A., Martinasso G., Reffo P., Colombatto S., et al. Mechanisms involved in growth inhibition induced by clofibrate in hepatoma cells. Toxicology 187 (2003) 149-159
43. Hashimoto F., Oguchi Y., Morita M., Matsuoka K., Takeda S., Kimura M., et al. PPARalpha agonists clofibrate and gemfibrozil inhibit cell growth, down-regulate hCG and up-regulate progesterone secretions in immortalized human trophoblast cells. Biochem Pharmacol 68 (2004) 313-321
44. Yang C.C., Wang Y.C., Wei S., Lin L.F., Chen C.S., Lee C.C., et al. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation. Cancer Res 67 (2007) 3229-3238
45. Leesnitzer L.M., Parks D.J., Bledsoe R.K., Cobb J.E., Collins J.L., Consler T.G., et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41 (2002) 6640-6650
46. Zhao Y., Xue Y., Oberley T.D., Kiningham K.K., Lin S.M., Yen H.C., et al. Overexpression of manganese superoxide dismutase suppresses tumor formation by modulation of activator protein-1 signaling in a multistage skin carcinogenesis model. Cancer Res 61 (2001) 6082-6088
47. Hardman W.E. (n-3) fatty acids and cancer therapy. J Nutr 134 (2004) 3427S-3430S
48. Gonzalez M.J. Fish oil, lipid peroxidation and mammary tumor growth. J Am Coll Nutr 14 (1995) 325-335
49. Girnun G.D., Naseri E., Vafai S.B., Qu L., Szwaya J.D., Bronson R., et al. Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 11 (2007) 395-406
50. Reddy R.C., Srirangam A., Reddy K., Chen J., Gangireddy S., Kalemkerian G.P., et al. Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer. Neoplasia 10 (2008) 597-603
51. Yokoyama Y., Xin B., Shigeto T., Umemoto M., Kasai-Sakamoto A., Futagami M., et al. Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther 6 (2007) 1379-1386